Synopsis Percutaneous coronary intervention (PCI) has been associated with a variable incidence of periprocedural myocardial infarction, which is independently associated with higher subsequent mortality. The present study evaluates the association between timing of drug administration before PCI and 30-day MACE in patients with ACS undergoing PCI. This week’s “ MED FACT ” discusses a randomized control trial from JAMA Cardiology, “ Timing of Loading Dose of Atorvastatin in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights From the SECURE-PCI Randomized Clinical Trial ”. Authors: R. D.
Lopes et. al. Key Takeaways Periprocedural loading doses of atorvastatin reduce the rate of MACE at 30 days, primarily in patients with ST-segment elevation myocardial infarction. Objective: The present study aims to determine whether periprocedural loading…
